ABSTRACT
No disponible
Subject(s)
Humans , Female , Middle Aged , Lymphatic Metastasis , Thyroid Neoplasms/surgery , Head and Neck Neoplasms , Colonic Neoplasms/pathologySubject(s)
Adenocarcinoma/pathology , Carcinoma/secondary , Lymphatic Diseases/etiology , Neck/pathology , Sigmoid Neoplasms/pathology , Thyroid Gland/pathology , Thyroid Neoplasms/secondary , Adenocarcinoma/therapy , Carcinoma/diagnostic imaging , Carcinoma/surgery , Carcinoma, Papillary , Chemotherapy, Adjuvant , Female , Humans , Lymph Node Excision , Lymphatic Diseases/diagnostic imaging , Lymphatic Diseases/surgery , Middle Aged , Neck/diagnostic imaging , Positron-Emission Tomography , Sigmoid Neoplasms/therapy , Thyroid Cancer, Papillary , Thyroid Gland/diagnostic imaging , Thyroid Neoplasms/diagnostic imaging , Thyroid Neoplasms/surgery , ThyroidectomyABSTRACT
INTRODUCTION: Chordoma is a rare malignant bone tumor. The outcome depends on the adequate surgical treatment with complete excision of the tumor with microscopic clear margins. MATERIALS AND METHODS: We performed a retrospective review of 13 cases of chordomas operated in our center between 1988 and 2009. RESULTS: All cases were treated with wide excision. Inadequate margins were found in seven patients. There were complications in ten patients and long-term sequels in 11 patients. Nine had recurrence within the first 2 years, six of which had inadequate margins. Five had metastatic disease, three of them with inadequate margins. During the follow-up, four patients died. In a posterior review, three patients survive and all of them had clear margins. CONCLUSIONS: In our experience, the best treatment is complete excision of the tumor with clear microscopic margins. When this is not possible, local recurrences increase and survival rate decreases.
Subject(s)
Bone Neoplasms/therapy , Chordoma/therapy , Rare Diseases/therapy , Sacrum/pathology , Aged , Bone Neoplasms/epidemiology , Bone Neoplasms/pathology , Bone Neoplasms/surgery , Chordoma/epidemiology , Chordoma/pathology , Chordoma/surgery , Cohort Studies , Female , Humans , Male , Middle Aged , Postoperative Complications/epidemiology , Rare Diseases/epidemiology , Rare Diseases/pathology , Rare Diseases/surgery , Retrospective Studies , Sacrum/surgery , Tertiary Care Centers/statistics & numerical data , Treatment Outcome , Tumor BurdenSubject(s)
Gastrointestinal Hemorrhage/etiology , Ulcer/complications , Vitelline Duct , Adolescent , Humans , MaleABSTRACT
The aim of this study is to analyze the clinical outcome of gastrointestinal stromal tumors (GISTs) and to determine new prognostic factors. We perform a retrospective study of all the patients diagnosed with GIST in any location and operated on between 2000 and 2008 at our institution. We analyzed 35 patients, 16 males (45.7%) and 19 females (54.3%), with a mean age of 64 +/- 13.8 years. The tumors were located in the stomach in 22 patients (62.9%), in the small bowel in 10 (28.6%), and the retroperitoneum in three (8.6%). Referring to gastric GIST, endoscopy revealed an ulceration in the mucosa in five cases, suggesting an epithelial neoplasm. In all these cases, pathology of the biopsy specimen was nonconclusive. Survival rate at 1 and 5 years was 94.3 and 88.6 per cent, respectively. Disease-free survival at 1 and 2 years was 91.4 and 88.6 per cent, respectively. Analyzing prognostic factors, a lower disease-free survival was observed among patients with constitutional syndrome at diagnosis (P = 0.000), small bowel GIST (P = 0.037), and tumors not expressing actin (P = 0.015). A lower global survival was observed among men (P = 0,036), patients with an abdominal mass (P = 0.033) or with constitutional syndrome (P = 0.007) at diagnosis and tumors at a retroperitoneal location (P = 0.0002). Gastric GIST may be confused with epithelial neoplasms, modifying the surgery. In our patients, masculine gender, constitutional syndrome and abdominal mass at diagnosis, small bowel and retroperitoneal location, and actin negative tumors are bad prognostic factors.
